📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Chemistry, manufacturing and controls document for TILA-278.
Why it exists. Chemistry, manufacturing, and controls evidence establishing product quality and consistency.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q / Q6B / Q8
| Field | Value |
|---|---|
| Document ID | M3-P |
| Version | 1.0 |
| Compound | TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific) |
| Standard | ICH M4Q / Q6B / Q8 |
| Confidentiality | Confidential |
Chemistry, manufacturing and controls document for TILA-278.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-07-08 | CMC/Quality | Initial issue |
No comments yet. Be the first to say something!
Drug product: TILA-278 solution for injection, 150 mg/mL, single-use prefilled syringe and autoinjector, for subcutaneous administration. Sponsor: Virtual Biopharma Inc. Cross-reference: Drug substance information is provided in Module 3.2.S; adventitious agent safety in Module 3.2.A.2; container-closure and device details are consolidated in Section 3.2.P.7.
TILA-278 drug product is a sterile, preservative-free, clear to slightly opalescent, colourless to pale-yellow aqueous solution for subcutaneous (SC) injection. The active ingredient is TILA-278, a recombinant humanized IgG1 bispecific monoclonal antibody comprising an anti-TL1A (TNFSF15) antagonist arm and an IL-22 receptor agonist arm, expressed in a Chinese Hamster Ovary (CHO) cell line (drug substance described in Module 3.2.S).
The drug product is presented at a single protein concentration of 150 mg/mL and supplied in two market presentations built on a common formulation and primary container:
Both presentations are qualitatively and quantitatively identical with respect to the formulated solution; they differ only in the assembled secondary device. The formulation contains an L-histidine buffer system, sucrose as a stabiliser and tonicity agent, L-arginine hydrochloride as a viscosity-reducing stabiliser, and polysorbate 80 as a surfactant. No antimicrobial preservative and no overage are included; the product is a single-use, single-dose presentation.
Table 3.2.P.1-1. Qualitative and quantitative composition
| Component | Function | Quality standard | Concentration | Amount per PFS (1.0 mL deliverable) |
|---|---|---|---|---|
| TILA-278 drug substance | Active | In-house (3.2.S) | 150 mg/mL | 150.0 mg |
| L-Histidine | Buffer | Ph. Eur. / USP–NF | ~1.2 mg/mL | ~1.2 mg |
| L-Histidine hydrochloride monohydrate | Buffer | Ph. Eur. / USP–NF | ~2.6 mg/mL | ~2.6 mg |
| Sucrose | Stabiliser / tonicity | Ph. Eur. / USP–NF | 75.3 mg/mL (220 mM) | 75.3 mg |
| L-Arginine hydrochloride | Stabiliser / viscosity reducer | Ph. Eur. / USP–NF | 5.3 mg/mL (25 mM) | 5.3 mg |
| Polysorbate 80 | Surfactant | Ph. Eur. / USP–NF | 0.4 mg/mL | 0.4 mg |
| Water for injection | Vehicle | Ph. Eur. / USP | q.s. to 1.0 mL | q.s. |
The buffer system provides a nominal target pH of 5.8. Target osmolality is approximately 300 mOsm/kg. A defined overfill is applied at the filling step to assure delivery of the 1.0 mL nominal dose from the syringe/device fluid path (see Section 3.2.P.3.2); it does not constitute an active overage.
Excipients are described in Section 3.2.P.4. All excipients are compendial and are used at levels consistent with parenteral products and with the FDA Inactive Ingredient Database / EMA precedent for SC monoclonal antibody products. There are no novel excipients.
3.2.P.2.1.1 Drug substance. The compatibility of the drug substance with the formulation excipients and with the container-closure/device materials was central to development. As a humanized IgG1 bispecific antibody, TILA-278 carries two independent binding functionalities that must both be preserved through formulation, manufacture, storage, and in-use handling: anti-TL1A neutralising activity and IL-22 receptor agonist activity. Both are monitored throughout development by orthogonal potency assays (Section 3.2.P.5.2). The principal molecular-degradation liabilities identified during characterisation of the drug substance and confirmed at drug-product level are:
3.2.P.2.1.2 Excipients. Each excipient was selected on established mechanistic and empirical grounds for a high-concentration SC mAb; there are no novel excipients and none is intended to exert therapeutic effect. See Table 3.2.P.2-1.
Table 3.2.P.2-1. Excipient selection rationale
| Excipient | Rationale for selection | Basis for level selected |
|---|---|---|
| L-Histidine / L-Histidine HCl | Effective buffering near the pH of maximum conformational and colloidal stability (pH 5.5–6.0); low injection-site irritation potential | pH mapping study; 20 mM provides adequate buffer capacity at low ionic strength |
| Sucrose | Preferential-exclusion stabiliser protecting against thermal and freeze/thaw-induced aggregation; contributes tonicity | Aggregation minimised across the sucrose range studied; level fixed to achieve target tonicity |
| L-Arginine HCl | Reduces solution viscosity at 150 mg/mL to enable SC injection through a fine-gauge staked-in needle; suppresses aggregation | Viscosity/stability trade-off study (Section 3.2.P.2.2) |
| Polysorbate 80 | Protects against interfacial (air–liquid and solid–liquid) stress during fill, shipping, and device actuation; mitigates agitation-induced particle formation | Agitation and pump-shear studies; level set above the protective threshold with margin for expected PS80 loss on storage |
Compatibility of the drug substance with each excipient and with the fully formulated product is demonstrated by the formulation-development and stability data in Sections 3.2.P.2.2 and 3.2.P.8.
Formulation history and comparability. A common qualitative formulation was maintained from first-in-human material through the pivotal Phase 2b induction study TILA278-201 and into the intended commercial presentation, supporting a straightforward analytical and clinical bridge. The clinical service formulation and the commercial formulation are quantitatively identical; the High and Low dose regimens evaluated in TILA278-201 (299 and 300 subjects, respectively) were achieved through the administered dose/number of injections rather than through any change in product concentration or composition. A formal formulation-comparability assessment (release plus a side-by-side stability arm) confirmed comparable quality attributes across the clinical and commercial formulation lots.
pH and buffer selection. A pH-mapping study across pH 5.0–6.5 identified a stability optimum near pH 5.8, at which aggregation rate (SE-HPLC), charge-variant drift (iCIEF), and fragmentation (CE-SDS) were jointly minimised under accelerated (25 °C) and stress (40 °C) conditions. Histidine was selected over acetate and citrate for its buffering capacity in this range and its favourable local-tolerability profile. The demonstrated pH stability region supports the release/shelf-life acceptance range of pH 5.5–6.1.
Stabiliser and tonicity. Sucrose was retained at 220 mM as a preferential-exclusion stabiliser and to bring the solution to physiological tonicity; it was preferred over trehalose on cost-of-goods and supply grounds with equivalent stabilising performance. No reducing-sugar-mediated glycation risk applies to sucrose.
Viscosity management — high-concentration SC formulation. At 150 mg/mL, dynamic viscosity is a critical developability attribute because it governs injection force and injection time through a staked-in 27-gauge thin-wall needle and drives autoinjector spring design. Without a viscosity modifier, the formulation exceeded the target injectability window; addition of 25 mM L-arginine hydrochloride reduced viscosity to approximately 12 mPa·s at 25 °C, within the range compatible with a fine-gauge SC autoinjector, while concurrently suppressing HMW formation. The arginine level represents the optimum from a viscosity-versus-conformational-stability trade-off study.
Surfactant selection and level. Polysorbate 80 was selected over polysorbate 20 for its interfacial protection during pumping, filling, shipping agitation, and device firing. Agitation and pump-shear challenge studies established the minimum protective concentration; the target of 0.4 mg/mL sits above this threshold with margin to accommodate polysorbate loss over shelf life (from oxidative and enzymatic/residual-hydrolase degradation). Polysorbate 80 content is a release and stability specification attribute, and its degradation is monitored as a potential source of sub-visible particulate.
Design of experiments and design space. A response-surface DoE varied protein concentration, pH, sucrose, arginine, and polysorbate 80 against aggregation, fragmentation, charge variants, viscosity, sub-visible particles, and both potencies. The resulting proven acceptable ranges support the control strategy; a formal expanded design space is not claimed. Overage: none. A fill overfill is justified in Section 3.2.P.3.2 solely to guarantee deliverable volume.
Physicochemical and biological characterisation of the formulated product confirms retention of higher-order structure and of both binding functionalities across the intended storage and in-use conditions, and is summarised in the stability data (Section 3.2.P.8). Sub-visible and sub-micron particles are characterised orthogonally by light obscuration (USP <788>) and micro-flow imaging (MFI) to distinguish proteinaceous from silicone-oil-derived populations.
The manufacturing process (thaw of drug substance → compounding/formulation → bioburden-reduction and sterilising-grade filtration → aseptic fill into PFS → stoppering → 100% visual inspection → autoinjector assembly → labelling/packaging) evolved from the clinical to the commercial scale without change to the unit operations or their sequence. Scale-up focused on preserving the drug substance's exposure limits to the identified stresses:
A summary comparison of clinical versus commercial process parameters and a batch-quality comparison support process comparability. Critical process parameters and their control are defined in Sections 3.2.P.3.3–3.2.P.3.4, and formal validation in 3.2.P.3.5.
The primary container-closure system is a 1 mL long Type I borosilicate glass barrel with a staked-in stainless-steel needle, a rigid needle shield (RNS) with an elastomeric needle-shield inner, and a coated bromobutyl rubber plunger stopper. Selection was governed by the sensitivities of a high-concentration mAb:
Container-closure integrity (CCI) is assured by a validated deterministic method (e.g., high-voltage leak detection / headspace) rather than by microbial-ingress challenge for routine control, in line with USP <1207>. Functional device performance is developed and verified per ISO 11608 for needle-based injection systems and is described further in Section 3.2.P.7. Full CCS composition, drawings, and specifications are provided in Section 3.2.P.7.
The drug product is a sterile-filtered, aseptically filled, single-use sterile solution with no antimicrobial preservative; an antimicrobial effectiveness test is therefore not applicable and none is included. Sterility assurance is provided by the validated aseptic process (Section 3.2.P.3.5), sterilising-grade filtration with post-use filter integrity testing, and container-closure integrity. Sterility (Ph. Eur. 2.6.1 / USP <71>) and bacterial endotoxins (Ph. Eur. 2.6.14 / USP <85>) are release specifications and are supported on stability by container-closure integrity (Section 3.2.P.8). Bioburden and endotoxin of the compounded bulk are controlled as in-process limits (Section 3.2.P.3.4).
As a single-use, ready-to-administer presentation, the product requires no reconstitution, dilution, or admixture, and no compatibility with infusion fluids or IV administration sets is required. Development compatibility studies addressed the relevant in-use and manufacturing contact surfaces:
Table 3.2.P.3-1. Manufacturers and responsibilities
| Facility / role | Responsibility |
|---|---|
| Virtual Biopharma Inc. — sterile fill-finish site | Thaw, compounding, filtration, aseptic filling, stoppering, visual inspection |
| Device assembly site | Autoinjector assembly, functional inspection |
| Packaging/labelling site | Secondary packaging, labelling, serialisation |
| QC laboratories | Release and stability testing |
| Batch release / QP site | Certification and release |
Each site holds a valid manufacturing authorisation/registration and operates under a current GMP status. Full names, addresses, and GMP certificates are provided in Module 1 / Section 3.2.A.1 as applicable.
Table 3.2.P.3-2. Batch formula (per nominal commercial batch of 2000 L compounded bulk)
| Component | Quantity per litre of formulated bulk | Function |
|---|---|---|
| TILA-278 drug substance | 150 g (as protein) | Active |
| L-Histidine | ~1.2 g | Buffer |
| L-Histidine hydrochloride monohydrate | ~2.6 g | Buffer |
| Sucrose | 75.3 g | Stabiliser / tonicity |
| L-Arginine hydrochloride | 5.3 g | Stabiliser / viscosity reducer |
| Polysorbate 80 | 0.4 g | Surfactant |
| Water for injection | q.s. to 1.0 L | Vehicle |
The target fill volume exceeds the 1.0 mL nominal deliverable volume by a validated overfill to compensate for hold-up in the syringe and device fluid path and to assure the labelled deliverable dose (Ph. Eur. 2.9.17 / USP <1>). This overfill does not increase the delivered active dose and is not an overage. Batch size and the number of finished units are documented in the batch record.
The commercial process is a standard aseptic fill-finish process for a monoclonal-antibody solution:
Storage and transport of finished product are at 2–8 °C, protected from light, and must not be frozen.
Table 3.2.P.3-3. Critical in-process controls
| Step | Parameter / test | Acceptance (proposed) |
|---|---|---|
| Compounding | Protein concentration | 150 mg/mL ± |
| Compounding | pH | 5.8 ± 0.3 |
| Compounding | Osmolality | Report; target ~300 mOsm/kg |
| Compounding | Polysorbate 80 content | Within release range |
| Pre-sterile-filtration bulk | Bioburden | ≤ 10 CFU/100 mL |
| Pre-sterile-filtration bulk | Endotoxin | ≤ EU/mL |
| Bulk holds | Hold time (pre-/post-filtration) | ≤ validated maximum |
| Sterile filtration | Filter integrity (pre/post) | Meets manufacturer's validated bubble-point/diffusion limit |
| Filling | Fill volume/weight | Target ± (statistically monitored) |
| Filling suite | Environmental monitoring / media-fill status | Within Grade A/ISO 5 limits; valid aseptic-process qualification |
| Visual inspection | Visible particulate / defects | Essentially free of visible particulates; AQL met |
| Assembly | Component functional checks | Meets device assembly spec |
Intermediates (thawed/pooled drug substance and compounded bulk) are transient and controlled by the in-process tests and hold-time limits above.
Process performance qualification (PPQ) was executed on three consecutive commercial-scale batches for each presentation, demonstrating that the process reproducibly yields product meeting all in-process and release acceptance criteria. The validation package comprises:
PPQ batch results met all acceptance criteria with no confirmed deviations affecting product quality. Continued process verification is established under the ongoing lifecycle programme.
All excipients — L-histidine, L-histidine hydrochloride monohydrate, sucrose, L-arginine hydrochloride, polysorbate 80, and water for injection — are controlled to their current compendial monographs (Ph. Eur. and/or USP–NF), supplemented where appropriate by additional supplier-agreed tests (e.g., a peroxide and total-oxidant limit and a specified oleic-acid/composition profile for polysorbate 80, given its role in oxidative degradation and particle formation).
Compendial methods are applied per the relevant monographs. Any non-compendial supplementary method (e.g., polysorbate 80 peroxide value) is described and referenced.
Compendial methods are used within their validated compendial scope and are verified for suitability in the sponsor's laboratories. Non-compendial supplementary methods are validated per ICH Q2.
Excipient specifications follow the applicable pharmacopoeial monographs; the supplementary polysorbate 80 controls are justified by the surfactant's mechanistic role in product stability and its identified degradation pathways (Section 3.2.P.2.2). Excipient grades and levels are consistent with approved parenteral SC monoclonal-antibody products.
No excipient is of human origin. Polysorbate 80 may be derived from vegetable or animal-sourced fatty acids; a plant (vegetable)-derived grade is specified, and TSE/BSE compliance is documented per the EMA note for guidance (EMEA/410/01) and Ph. Eur. 5.2.8. Supporting statements/certificates are in Section 3.2.A.2 as applicable. No excipient poses a viral- or TSE-safety concern.
There are no novel excipients; all are established for parenteral use and present in the FDA Inactive Ingredient Database / EU-approved products at or above the levels used here.
The drug-product specification (release and shelf-life) is defined per ICH Q6B and includes appearance, identity, purity/impurities, potency (dual, reflecting the bispecific mechanism), general tests, and safety tests. Certain attributes (sterility, endotoxin) are release-only, verified on stability by container-closure integrity. Proposed acceptance criteria are given in Table 3.2.P.5-1.
Table 3.2.P.5-1. Drug product specification (proposed)
| Attribute | Analytical procedure | Release acceptance criterion | Shelf-life acceptance criterion |
|---|---|---|---|
| Appearance (visual) | Visual (Ph. Eur. 2.2.1 / 2.2.2) | Clear to slightly opalescent, colourless to pale-yellow solution, essentially free of visible particles | Same |
| Visible particulates | Ph. Eur. 2.9.20 / USP <790> | Essentially free of visible particulates | Same |
| pH | Ph. Eur. 2.2.3 | 5.5 – 6.1 | 5.5 – 6.1 |
| Osmolality | Ph. Eur. 2.2.35 | Report result (target ~300 mOsm/kg) | Report result |
| Protein concentration | UV spectrophotometry (A280) | 150 mg/mL ± | Same |
| Extractable / deliverable volume | Ph. Eur. 2.9.17 / USP <1> | ≥ 1.0 mL | ≥ 1.0 mL |
| Purity — monomer / HMW | SE-HPLC | Monomer ≥ 95 %; HMW ≤ 95 % | Monomer ≥ 95 %; HMW ≤ 95 % |
| Purity — non-reduced | CE-SDS (non-reduced) | Main ≥ 90 % | Main ≥ 90 % |
| Purity — reduced | CE-SDS (reduced) | Sum of principal chains ≥ 90 % | Same |
| Charge variants | iCIEF | Main / acidic / basic within ranges | Within ranges |
| Identity | iCIEF profile + potency-based identity (dual binding) | Consistent with reference standard | n/a (release) |
| Potency — anti-TL1A neutralisation | Cell-based reporter bioassay | 80 – 125 % of reference | 80 – 125 % of reference |
| Potency — IL-22R agonism | Cell-based reporter bioassay | 80 – 125 % of reference | 80 – 125 % of reference |
| Polysorbate 80 content | HPLC-ELSD/CAD | 0.4 mg/mL ± | Within range |
| Sub-visible particles | Light obscuration, USP <788> | ≥10 µm ≤ 6000/container; ≥25 µm ≤ 600/container | Same |
| Sterility | Ph. Eur. 2.6.1 / USP <71> | Sterile | Assured by CCI |
| Bacterial endotoxins | Ph. Eur. 2.6.14 / USP <85> | ≤ EU/mg | n/a (release) |
| Container-closure integrity | USP <1207> deterministic method | Pass | Pass |
Device/combination-product functional attributes (autoinjector and PFS) are specified and tested per Section 3.2.P.7 (e.g., injection time, delivered dose accuracy, activation force, break-loose/glide force, needle-safety function).
All non-compendial procedures are validated in accordance with ICH Q2(R2) for the relevant characteristics (specificity, accuracy, precision, linearity, range, quantitation/detection limits as applicable). The potency bioassays are validated with particular attention to relative-accuracy, precision, and system-suitability, and are calibrated against the qualified reference standard (Section 3.2.P.6). Compendial methods are verified for suitability.
Representative batch-analysis data are provided for clinical (including TILA278-201 supply), PPQ, and stability-registration batches, demonstrating consistent manufacture and conformance to the proposed specification. All reported batches met acceptance criteria for both potencies, size and charge purity, and safety tests.
Table 3.2.P.5-2. Batch analysis summary (representative)
| Attribute | Clinical batch(es) | PPQ batch 1 | PPQ batch 2 | PPQ batch 3 |
|---|---|---|---|---|
| Protein conc. (mg/mL) | ||||
| Monomer (SE-HPLC, %) | ||||
| HMW (%) | ||||
| Main (CE-SDS NR, %) | ||||
| Main (iCIEF, %) | ||||
| Anti-TL1A potency (%) | ||||
| IL-22R potency (%) | ||||
| Sub-visible ≥10 µm (/container) |
Product-related impurities/variants (HMW aggregates, LMW fragments, charge variants, and any bispecific-specific mispaired species) are characterised as described in the drug-substance dossier (3.2.S.3) and confirmed at the drug-product level. Process-related impurities are controlled predominantly by the drug-substance process (host-cell protein, residual DNA, Protein A, and process reagents; see 3.2.S). Product-specific to the drug product are the container/device-derived potential impurities — silicone oil, tungsten, and elastomer/adhesive leachables — controlled by container selection and E&L qualification (Sections 3.2.P.2.4 and 3.2.P.7). No new drug-product impurity requires additional qualification beyond those addressed in the drug-substance and E&L assessments.
Acceptance criteria are justified by the combination of ICH Q6B principles, batch-manufacturing history and process capability, clinical-exposure (qualification) ranges bracketed by TILA278-201 and any supporting studies, stability behaviour, and assay capability. Potency ranges bound the clinically qualified activity for both mechanistic arms. Aggregate and sub-visible particle limits are set to protect immunogenicity-relevant quality, consistent with the low, non-dose-dependent injection-site-reaction finding observed in TILA278-201 (injection-site reactions were the principal drug-attributable adverse finding, without a dose-dependent trend). Safety-test limits follow compendial and endotoxin-per-dose calculations.
A two-tiered reference-standard system is employed: a qualified primary reference standard traceable to clinical (including TILA278-201) and toxicology material, and working reference standards qualified against the primary standard. Reference standards are characterised for identity, size and charge purity, higher-order structure, and both potencies, and are stored under conditions supporting long-term stability. Qualification, requalification, and bridging protocols are defined and executed under the lifecycle programme. The same reference standard system anchors the drug-substance and drug-product potency and purity methods to assure comparability across the program.
Primary packaging. 1 mL long Type I borosilicate glass syringe barrel with a staked-in 27-gauge thin-wall stainless-steel needle; rigid needle shield; and a fluoropolymer-laminated bromobutyl rubber plunger stopper. Low-tungsten barrels and controlled (cross-linked) siliconisation are specified (rationale in Section 3.2.P.2.4).
Presentations.
Specifications and drawings. Dimensional and material specifications, supplier drawings, and quality standards for each component (barrel, needle, shield, stopper, plunger rod, safety guard, autoinjector subassemblies) are provided. Elastomeric and glass components comply with the relevant Ph. Eur./USP requirements for parenteral containers and closures.
Combination-product / device performance. The autoinjector and PFS are combination products. Design and verification follow ISO 11608 (needle-based injection systems), with a design-controls/risk-management framework (ISO 13485 / ISO 14971) and human-factors/usability engineering supporting safe self-administration by UC patients. Functional performance is verified at release and monitored on stability, including:
Table 3.2.P.7-1. Device functional attributes (proposed)
| Attribute | Method basis | Acceptance (proposed) |
|---|---|---|
| Delivered (dose) volume/accuracy | ISO 11608-1 | ≥ 1.0 mL; within 5 % of label |
| Injection time (autoinjector) | ISO 11608-5 | ≤ s |
| Activation force | ISO 11608-5 | Within N |
| Break-loose / glide force (PFS) | ISO 11608-3 | Within N |
| Needle-safety / lock-out function | ISO 11608-1 | Functions as intended (pass) |
| Container-closure integrity | USP <1207> | Pass |
Extractables and leachables. An E&L programme with toxicological risk assessment covers the glass, needle adhesive, elastomer, and silicone; results support patient safety across shelf life with no leachable exceeding its qualified threshold.
Stability of TILA-278 drug product is being established under ICH Q1A(R2), Q1B, and Q5C on registration batches of each presentation, stored in the final container-closure system in the intended orientation. The study design is summarised in Table 3.2.P.8-1.
Table 3.2.P.8-1. Stability study design
| Condition | Temperature / RH | Orientation | Time points | Purpose |
|---|---|---|---|---|
| Long-term | 5 °C ± 3 °C | Upright + horizontal | 0, 3, 6, 9, 12, 18, 24, 36 mo | Shelf-life assignment |
| Accelerated | 25 °C ± 2 °C / 60% RH ± 5% | Upright | 0, 1, 3, 6 mo | Degradation-pathway / support |
| Stress | 40 °C ± 2 °C / 75% RH ± 5% | Upright | 0, 1, 2, 3 mo | Stability-indicating support |
| Photostability | ICH Q1B option 2 | — | Single challenge | Light sensitivity |
| In-use / thermal excursion | Single excursion to ≤ 30 °C | Upright | Defined interval | In-use labelling |
| Agitation/transport | Simulated shipping | — | Post-challenge | Distribution robustness |
Findings. Under the long-term 5 °C condition, all quality attributes — appearance, pH, protein concentration, size purity (SE-HPLC monomer/HMW; CE-SDS), charge distribution (iCIEF), both potencies, sub-visible particles, polysorbate 80 content, and container-closure integrity — remain within the proposed acceptance criteria through the data available to date, supporting the proposed shelf life. The primary temperature-dependent degradation observed under accelerated and stress conditions is an increase in HMW aggregate and acidic charge variants with associated modest potency change, consistent with the pathways identified in development; these changes are slow at the recommended storage condition. Photostability confirms the product is light-sensitive and must be stored in its carton, protected from light. Simulated-transport and in-use excursion challenges support the proposed handling and excursion allowances.
Proposed storage statement and shelf life. Store at 2–8 °C. Do not freeze. Keep in the original carton to protect from light. Do not shake. Proposed shelf life: 24 months at 2–8 °C, to be extended as real-time data accrue under the post-approval protocol.
In-use statement. The product may be kept at room temperature (up to 30 °C) for a single period of up to 14 days within the labelled shelf life; after room-temperature storage it must not be returned to the refrigerator, and any unused product is discarded. Allow the product to reach room temperature before injection; do not warm by any other means.
At least one commercial-scale batch per presentation per year (annual batches) will be placed on the long-term stability program under the protocol above and monitored to the end of the assigned shelf life. The sponsor commits to (i) complete long-term studies on the primary registration batches, (ii) place the first three commercial-scale batches of each presentation on long-term stability, and (iii) report out-of-specification/out-of-trend results and any consequent shelf-life or labelling changes to the agency. Any change extending or modifying the shelf life will be supported by data under this protocol.
Full tabulated and, where informative, graphical stability data for each registration batch, presentation, condition, and attribute are provided in this section. Data are trended against the shelf-life acceptance criteria; no attribute shows a trend projected to breach acceptance within the proposed shelf life at the recommended storage condition.
Prepared in accordance with ICH M4Q (CTD Quality), ICH Q6B, and ICH Q8(R2); cross-references to Q1A(R2)/Q1B/Q5C (stability), Q2(R2) (analytical validation), Q5A(R2)/Q5E (viral safety and comparability, in 3.2.S/3.2.A), and Q9/Q10 (quality risk management and pharmaceutical quality system).